JMP Securities Reaffirms Market Outperform Rating for Aquestive Therapeutics (NASDAQ:AQST)

JMP Securities reaffirmed their market outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note published on Monday, Benzinga reports. They currently have a $9.00 price target on the stock.

A number of other research firms have also recently commented on AQST. Leerink Partners reissued an outperform rating and set a $12.00 target price (up from $10.00) on shares of Aquestive Therapeutics in a research report on Monday. HC Wainwright raised their target price on Aquestive Therapeutics from $9.00 to $10.00 and gave the company a buy rating in a research note on Monday. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of Buy and an average price target of $8.67.

Aquestive Therapeutics Trading Up 0.6 %

NASDAQ:AQST opened at $4.79 on Monday. The firm’s fifty day simple moving average is $4.29 and its 200 day simple moving average is $3.68. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23. The firm has a market capitalization of $436.08 million, a price-to-earnings ratio of -11.33 and a beta of 2.84.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.08. The company had revenue of $20.10 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the previous year, the company earned ($0.10) EPS. On average, analysts predict that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. acquired a new position in Aquestive Therapeutics in the second quarter worth about $27,000. SG Americas Securities LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter worth approximately $54,000. Lazard Asset Management LLC increased its holdings in shares of Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after acquiring an additional 15,601 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at approximately $76,000. Finally, Financial Advocates Investment Management lifted its stake in Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.